Chiropractic Medicare Coverage Modernization Act of 2025 This bill expands Medicare coverage of chiropractic services to include all services provided by chiropractors, rather than only subluxation corrections through manual manipulation of the spine.
This bill modifies how Medicare Advantage plans are paid to address regional payment disparities and ensure funds reach patient care. It sets a minimum 70% floor for geographic adjustments in payment calculations starting in 2026, preventing some areas from receiving disproportionately low payments. Additionally, it requires that at least 50% of any payment increase tied to this new rule must be directed toward basic healthcare benefits for enrollees. The bill directly affects Medicare Advantage plans, their providers, and seniors enrolled in these plans who receive care through these programs.
Preserving Patient Access to Home Infusion Act This bill specifically includes pharmacy services and home infusion drugs that are administered without a pump as part of covered home infusion therapy under Medicare. The bill also allows nurses and physician assistants to establish and review the plan of care for home infusion therapy, and it specifies that payment may be made regardless of whether a practitioner is physically present in the home at the time the drug is administered.
HR 4773, the ACO Assignment Improvement Act of 2025, amends Medicare's Shared Savings Program rules to change how beneficiaries are assigned to Accountable Care Organizations (ACOs). It adds a new provision requiring ACOs to include primary care services provided by their professionals in beneficiary assignment calculations starting January 1, 2027. This directly affects Medicare beneficiaries enrolled in ACOs and the ACOs themselves, as it modifies the criteria used to determine which beneficiaries are counted toward an ACO's performance. The change aims to better align beneficiary assignments with primary care service delivery under the program.
HR 786 extends Medicare incentive payments for providers participating in "eligible alternative payment models" (like bundled care programs) by adjusting key timeline and percentage references in the Social Security Act. It specifically delays the expiration of these incentives from 2026 to 2027 for certain payments (adding a 3.53% rate for 2027) and extends subsequent years' references accordingly. This bill directly affects Medicare providers using alternative payment models by preserving their access to these financial incentives for an additional year. The key mechanism is technical, updating specific years and payment percentages in Medicare law without changing the underlying program structure. The bill does not create new programs but ensures existing incentives continue for providers in 2027 and beyond.
This bill would expand Medicare Part B coverage to include medical nutrition therapy for beneficiaries with a wider range of chronic conditions beyond current limits (diabetes and kidney disease). It specifically adds conditions like obesity, hypertension, eating disorders, cancer, gastrointestinal diseases, and HIV to the list of covered illnesses, allowing coverage for prevention, management, or treatment. The bill also allows more healthcare providers - including dietitians, nurse practitioners, and clinical psychologists - to deliver these services. This change would directly affect millions of Medicare beneficiaries managing these conditions who previously lacked coverage for medically necessary nutrition therapy.
Lung Cancer Screening and Prevention Act of 2025 This bill authorizes Medicare coverage of additional types of lung cancer screening tests that are approved by the Food and Drug Administration, regardless of whether they are recommended by the United States Preventive Services Task Force. The Centers for Medicare & Medicaid Services must set coverage and payment limits for such tests. (Currently, Medicare covers screening tests for the early detection of lung cancer if they are recommended by the task force.)
This bill exempts certain orally administered drugs from Medicare Part D's manufacturer discount program. Specifically, it excludes drugs that: (1) received FDA approval under the standard new drug application process, and (2) have been granted a narrow CMS exception allowing them to be treated as noninnovator drugs under Medicaid rebates. The exemption applies directly to these specific drugs meeting both criteria, altering how their costs are calculated under Medicare Part D. This change affects drug manufacturers and Medicare beneficiaries by modifying the discount structure for these particular medications.
This bill would require Medicare to cover early detection screening tests for Alzheimer's disease and related dementias starting January 1, 2028. It defines eligible tests as FDA-cleared genomic blood tests, blood product analyses, or equivalent medical imaging methods (like protein expression or whole genome sequencing) that detect pre-symptomatic or early-stage conditions. Medicare beneficiaries would receive this coverage without cost-sharing for these specific screenings. The bill amends Medicare coverage rules to explicitly include these tests under Section 1861(nnn) of the Social Security Act.
S 553, the SOLES Act, requires increased Medicare payments for sole community hospitals in Alaska and Hawaii. If a hospital's payment under Medicare's outpatient system is less than 94% of its reasonable costs, the payment must be raised to cover the shortfall. This directly affects the 11 sole community hospitals in these states that are the only providers of acute care in their communities. The bill mandates that these extra payments don't count toward budget neutrality rules or affect patient copayments, and requires the Secretary to issue implementing regulations within six months of enactment.